Langfristige, prospektive, multizentrische Beobachtungsstudie zur Erhebung von Daten zum Behandlungsmuster von SecukinumAb bei erwachsenen Patienten mit mittelschwerer bis schwerer Hidradenitis suppurativa in einer realen Bevölkerung. (ANIMA)
Langfristige, prospektive, multizentrische Beobachtungsstudie zur Erhebung von Daten zum Behandlungsmuster von SecukinumAb in einer realen Bevölkerung bei erwachsenen Patienten mit mittelschwerer bis schwerer Hidradenitis suppurativa (HS) (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Aachen, Deutschland, 52064
- Novartis Investigative Site
-
Ahaus, Deutschland, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, Deutschland, 09456
- Novartis Investigative Site
-
Bad Steben, Deutschland, 95138
- Novartis Investigative Site
-
Baden-Baden, Deutschland, 76530
- Novartis Investigative Site
-
Berlin, Deutschland, 12159
- Novartis Investigative Site
-
Berlin, Deutschland, 13595
- Novartis Investigative Site
-
Bielefeld, Deutschland, 33647
- Novartis Investigative Site
-
Bochum, Deutschland, 44791
- Novartis Investigative Site
-
Bonn, Deutschland, 53105
- Novartis Investigative Site
-
Brandenburg, Deutschland, 14776
- Novartis Investigative Site
-
Bremen, Deutschland, 28359
- Novartis Investigative Site
-
Buxtehude, Deutschland, 21614
- Novartis Investigative Site
-
Bückeburg, Deutschland, 31675
- Novartis Investigative Site
-
Chemnitz, Deutschland, 09117
- Novartis Investigative Site
-
Chemnitz, Deutschland, 09113
- Novartis Investigative Site
-
Cologne, Deutschland, 51065
- Novartis Investigative Site
-
Delitzsch, Deutschland, 04509
- Novartis Investigative Site
-
Dessau, Deutschland, 06847
- Novartis Investigative Site
-
Dorsten, Deutschland, 46282
- Novartis Investigative Site
-
Dortmund, Deutschland, 44137
- Novartis Investigative Site
-
Dresden, Deutschland, 01309
- Novartis Investigative Site
-
Düren, Deutschland, 52349
- Novartis Investigative Site
-
Emsdetten, Deutschland, 48282
- Novartis Investigative Site
-
Erlangen, Deutschland, 91054
- Novartis Investigative Site
-
Falkenberg, Deutschland, 04895
- Novartis Investigative Site
-
Falkensee, Deutschland, 14612
- Novartis Investigative Site
-
Freising, Deutschland, 85354
- Novartis Investigative Site
-
Geilenkirchen, Deutschland, 52511
- Novartis Investigative Site
-
Gera, Deutschland, 07548
- Novartis Investigative Site
-
Gernsbach, Deutschland, 76593
- Novartis Investigative Site
-
Gladbeck, Deutschland, 45964
- Novartis Investigative Site
-
Großenhain, Deutschland, 01558
- Novartis Investigative Site
-
Hamburg, Deutschland, 20246
- Novartis Investigative Site
-
Hamburg, Deutschland, 22143
- Novartis Investigative Site
-
Hanover, Deutschland, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, Deutschland, 77716
- Novartis Investigative Site
-
Hofgeismar, Deutschland, 34369
- Novartis Investigative Site
-
Jena, Deutschland, 07743
- Novartis Investigative Site
-
Jülich, Deutschland, 52428
- Novartis Investigative Site
-
Karlsruhe, Deutschland, 76133
- Novartis Investigative Site
-
Kempen, Deutschland, 47906
- Novartis Investigative Site
-
Lübeck, Deutschland, 23538
- Novartis Investigative Site
-
Magdeburg, Deutschland, 39120
- Novartis Investigative Site
-
Magdeburg, Deutschland, 39104
- Novartis Investigative Site
-
Mainz, Deutschland, 55116
- Novartis Investigative Site
-
Marburg, Deutschland, 35043
- Novartis Investigative Site
-
Minden, Deutschland, 32429
- Novartis Investigative Site
-
Mönchengladbach, Deutschland, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, Deutschland, 21629
- Novartis Investigative Site
-
Nuremberg, Deutschland, 90419
- Novartis Investigative Site
-
Oberasbach, Deutschland, 90522
- Novartis Investigative Site
-
Oelde, Deutschland, 59302
- Novartis Investigative Site
-
Peitz, Deutschland, 03185
- Novartis Investigative Site
-
Potsdam, Deutschland, 14469
- Novartis Investigative Site
-
Remscheid, Deutschland, 42897
- Novartis Investigative Site
-
Selters, Deutschland, 56242
- Novartis Investigative Site
-
Simmern, Deutschland, 55469
- Novartis Investigative Site
-
Soest, Deutschland, 59494
- Novartis Investigative Site
-
Stolberg, Deutschland, 52222
- Novartis Investigative Site
-
Unna, Deutschland, 59423
- Novartis Investigative Site
-
Wittlich, Deutschland, 54316
- Novartis Investigative Site
-
Wuppertal, Deutschland, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Deutschland, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, Deutschland, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, Deutschland, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, Deutschland, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, Deutschland, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, Deutschland, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, Deutschland, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Deutschland, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, Deutschland, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, Deutschland, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, Deutschland, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, Deutschland, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Deutschland, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Deutschland, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Deutschland, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, Deutschland, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, Deutschland, 06886
- Novartis Investigative Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
Beschreibung
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of patients receiving up-titration
Zeitfenster: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
Zeitfenster: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
Zeitfenster: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
Zeitfenster: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
Zeitfenster: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Zeitfenster: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
Zeitfenster: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Zeitfenster: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Zeitfenster: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Zeitfenster: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
Zeitfenster: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Zeitfenster: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CAIN457MDE01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .